Description
The authors explicitly state it remains incompletely characterized whether GLP-1 RAs consistently engage neural circuits underlying cognition and psychopathology. This knowledge gap limits translation of promising preclinical neuroprotective effects to clinical applications in Alzheimer’s and Parkinson’s disease.
Gap type: open_question Source paper: Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (2025, Neurology and therapy, PMID:40172827)